Formulation and Evaluation of Transdermal Drug Delivery System Containing Lornoxicam.

The present study was undertaken to develop site-specific drug delivery system of lornoxicam for treatment of arthritis, pain etc., which has excellent activity on inhibition of cyclooxygenase-1 and cyclooxygenase-2 enzymes. Formulations were developed by various polymers such as Hydroxy propyl Cellulose and Eudragit RL-100 by solvent casting technique by utilizing plasticizer PEG-400 & DBT. The formulations were evaluated for thickness, folding endurance, weight variation, drug content, percent moisture loss & absorption, tensile strength etc. In vitro drug release study was also carried out by using PBS pH 7.4; the samples were analyzed UV-spectrophotometrically at 374 nm. Compatibility study was carried out by FT-IR and DSC, which revealed no interaction between drug and polymers. Formulations shown good uniformity of drug content, there was no any kind of effect on moisture loss test. Weight and thickness of the patches was found to be uniform. Formulation F6 shows the release of drug 96.74% at the end of 12 h and was considered as a best formulation. Accelerated stability study indicated the formulations were remained stable both physically and chemically. Formulations prepared with dibutyl phthalate have shown to effect on tensile strength and folding endurance when compared with PEG-400.